Genscript Biotech - H (1548.HK): Investor Day afternoon takeaways: Scaling AIDD capacity to help beat FY26 guidance

We attended the afternoon session of GenScript's Investor Day, where management provided further detail on capability development, capacity expansion and market growth opportunities. The discussion largely reinforced the existing investment case, but with limited additional financial or new order guidance, which might explain why the stock went down >7% (vs. HSHCI down 1.3%) in the afternoon. Management's emphasis was on building an integrated validation platform capable of supporting larger experiment volumes, more complex molecules and shorter customer order cycles. We see the most relevant takeaways as improving repeat-order activity, expansion of automated capacity and a disciplined approach to converting that capacity into revenue and cash flow. Management also expects profit growth to continue outpacing revenue growth in 2H26. Overall, we think the company would beat its FY26 revenue guidance and could also beat our FY27 AIDD revenue growth estimate of 108%.